MedTrace Logo

Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)

NCT02978118 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2025-09-09

No results posted yet for this study

Summary

This pilot study purpose of this study is to describe peripheral circulating immune cell profiles at baseline and change on treatment with immune checkpoint inhibitors in renal cell carcinoma and urothelial carcinoma.

Conditions

  • Carcinoma, Renal Cell
  • Carcinoma, Urothelial

Interventions

DEVICE

Immune cell and CTC detection procedures

Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)

Sponsors & Collaborators

  • University of Wisconsin, Madison

    collaborator OTHER

  • Duke University

    lead OTHER

Principal Investigators

  • Daniel George, MD · Duke University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-07
Primary Completion
2028-10-31
Completion
2028-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02978118 on ClinicalTrials.gov